Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 17/20 | 0.68 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18253629 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL24123152 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20910851 | 0.99 | FOLH1 (0.66) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26758628 | 0.95 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26757300 | 0.95 | FOLH1 (0.65) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15383531 | 0.93 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL10134716 | 0.93 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26757303 | 0.90 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26757838 | 0.90 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL24491153 | 0.90 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372433-A1 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | KING'S COLLEGE LONDON (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FUZIONAIRE DIAGNOSTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20210393809-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | Universität Heidelbert (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210177857-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | PFIZER INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | PFIZER INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
| US-20190269617-A1 | Methods of Controlling Morphology of Polymeric Nanoparticles | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190099374-A1 | STABLE FORMULATIONS FOR LYOPHILIZING THERAPEUTIC PARTICLES | PFIZER INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-8357401-B2 | Stable formulations for lyophilizing therapeutic particles | BIND BIOSCIENCES, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8318211-B2 | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8211473-B2 | Stable formulations for lyophilizing therapeutic particles | BIND BIOSCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8206747-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120140790-A1 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Termperature or High Molecular Weight Copolymers | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
| US-20110275704-A1 | Stable Formulations for Lyophilizing Therapeutic Particles | PFIZER INC. | 2011-11-10 | — | — | US | disclosed |
| US-20100104655-A1 | Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100069426-A1 | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275704-A1 | Stable Formulations for Lyophilizing Therapeutic Particles | PRNP, SYNCRIP, LPXN | FOLH1 1774/4885NAALAD2 2971/4885RIMKLA 3673/4885 |
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FRS2, PAICS, FGF23 | FOLH1 183/4885NAALAD2 1955/4885RIMKLA 4365/4885 |
| US-20230372433-A1 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | ARGLU1, GLUL, DDX3X | FOLH1 82/4885NAALAD2 525/4885RIMKLA 437/4885 |
| US-20100069426-A1 | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same | RICTOR, MTOR, MAPKAP1 | FOLH1 2346/4885NAALAD2 3804/4885RIMKLA 2143/4885 |
| US-20100104655-A1 | Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same | TUBB3, TUBA1A, TUBB6 | FOLH1 92/4885NAALAD2 2177/4885RIMKLA 1150/4885 |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | FOLH1 234/4885NAALAD2 1095/4885RIMKLA 4322/4885 |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885NAALAD2 2614/4885RIMKLA 1707/4885 |
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | CD47, CD274, PDCD1 | FOLH1 8/4885NAALAD2 869/4885RIMKLA 1404/4885 |
| US-20190269617-A1 | Methods of Controlling Morphology of Polymeric Nanoparticles | CLTB, NCL, ACTB | FOLH1 828/4885NAALAD2 3320/4885RIMKLA 1643/4885 |
| US-20210393809-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | KLK3, PSMA3, FOLH1 | FOLH1 3/4885NAALAD2 633/4885RIMKLA 2649/4885 |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | CTSA, GAA, EEA1 | FOLH1 135/4885NAALAD2 1736/4885RIMKLA 3209/4885 |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | FOLH1 51/4885NAALAD2 3323/4885RIMKLA 482/4885 |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885NAALAD2 2442/4885RIMKLA 1489/4885 |
| US-20190099374-A1 | STABLE FORMULATIONS FOR LYOPHILIZING THERAPEUTIC PARTICLES | PRNP, SYNCRIP, LPXN | FOLH1 1774/4885NAALAD2 2971/4885RIMKLA 3673/4885 |
| US-20210177857-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | TP53, HNRNPH3, VHL | FOLH1 336/4885NAALAD2 1694/4885RIMKLA 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.